Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

36.51USD
9 Dec 2016
Change (% chg)

$0.45 (+1.25%)
Prev Close
$36.06
Open
$36.08
Day's High
$37.15
Day's Low
$36.07
Volume
6,118,816
Avg. Vol
7,054,809
52-wk High
$55.51
52-wk Low
$33.60

Latest Key Developments (Source: Significant Developments)

Mylan developing cost reduction initiatives to streamline operations globally
Wednesday, 7 Dec 2016 08:22am EST 

Mylan NV : Mylan NV - announced restructuring programs in certain locations . Company is currently developing details of cost reduction initiatives, including workforce actions . Mylan NV -restructuring programs in locations representing initial steps in series of actions that are anticipated to streamline its operations globally . Mylan NV - currently developing details of cost reduction initiatives, including workforce actions and other potential restructuring activities .Mylan NV - as part of process, co anticipates that less than 10 percent of its global workforce may be impacted across all geographies and businesses.  Full Article

U.S. senator Chuck Grassley says Mylan declining to testify at judiciary committee hearing
Monday, 21 Nov 2016 11:54am EST 

U.S. Senator Chuck Grassley:Says Mylan declining to testify at judiciary committee hearing on potential settlement between Mylan and DOJ.  Full Article

Mylan NV sees 2016 sales for EpiPen in U.S. of $1,100 mln - SEC Filing
Monday, 26 Sep 2016 01:03pm EDT 

Mylan Nv : Mylan NV sees 2016 sales for EpiPen in U.S. $1,100 MLN - SEC Filing . Says in U.S., sees EpiPen 2016 estimated gross profit of $825 million - SEC Filing . For EpiPen , sees 8 million U.S. Pens sold in 2016 . Sees 2016 EpiPen operating profit in U.S. (not all regions) of $671 million versus reported 2015 operating profit of $498 million . "Does not intend in the future to provide product level profitabilty analysis for EpiPen " .Sees 2016 EpiPen net product profitability in U.S. (not all regions) of $419 million versus reported net product profitability for EpiPen of $312 million in 2015.  Full Article

BRIEF-Mylan says pre-tax Epipen profits are actually 60 pct higher than what it told Congress last week - CNBC, citing Dow Jones
Monday, 26 Sep 2016 09:05am EDT 

Sept 26 (Reuters) - • Mylan says pre-tax Epipen profits are actually 60 pct higher than what it told Congress last week - CNBC, citing Dow Jones:.  Full Article

New York probes Mylan over Epipen sales to schools
Tuesday, 6 Sep 2016 12:39pm EDT 

Mylan NV : New York attorney general says he launches antitrust investigation into Mylan over epipen . Nyag eric schneiderman says preliminary review identifies potential anticompetitive terms in epipen sales contracts with schools.  Full Article

NYC Comptroller Scott Stringer urges Mylan to name independent board chair
Thursday, 1 Sep 2016 03:24pm EDT 

New York City Comptroller Scott Stringer to Mylan: New York City Comptroller Scott Stringer writes to Mylan's Chair, Nominating and Governance Committee regarding effects of EpiPen price hikes . Urges Mylan board to name an independent board chair . "Express alarm" with Mylan's "exorbitant" price hikes for EpiPen . Asks Mylan to remove non-independent directors from the audit committee and nominating and governance committee . "Mylan's gross mismanagement of its EpiPen pricing strategy exacerbates the company's protracted history of weak board oversight" . "Mylan has failed to establish independent board leadership" . Urges Mylan to ensure each key board committee is comprised exclusively of independent directors with no material relationship to co . Urge co to establish clear and robust board-level oversight of the risks inherent by co's drug price strategy . Urges Mylan to provide clearer disclosure of co's drug pricing risks by annually detailing process and oversight co follows ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

U.S. Representatives seek details from Mylan on EpiPens price rise
Monday, 29 Aug 2016 02:36pm EDT 

: Representatives Jason Chaffetz, Elijah Cummings Of U.S. House Committee On Oversight And Government Reform Send Letter To Mylan CEO . Representatives Jason Chaffetz, Elijah Cummings Of U.S. House Committee On Oversight And Government Request Documents On Mylan's EpiPen's Price Rise Further company coverage: [MYL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Mylan to launch first generic to EpiPen® auto-injector at a List Price of $300 per Two-Pack Carton
Monday, 29 Aug 2016 06:00am EDT 

Mylan NV : To launch first generic to EpiPen® auto injector at a list price of $300 per two-pack carton, a more than 50% discount to the brand product . Mylan also intends to continue to market and distribute branded epipen . Mylan nv says intends to initiate a direct ship program in conjunction with launch of generic at $300 generic list price . Expects to launch launch epipen auto-injector in several weeks, pending completion of labeling revisions .Both augmented patient assistance program and $300 savings card announced last week will remain in place for brand product.  Full Article

Express Scripts chief medical officer says Mylan has a monopoly on the EpiPen
Thursday, 25 Aug 2016 04:03pm EDT 

: Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - "Mylan could lower the price today" . Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - Mylan has a monopoly on the epipen Further company coverage: [MYL.O ESRX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Moody's says Teva's loss of two copaxone patents is credit negative
Thursday, 25 Aug 2016 02:33pm EDT 

Moody's Ratings : Teva's loss of two copaxone patents is credit negative .Moody's on Teva Pharmaceutical - there is no change to Teva Pharmaceutical Industries LTD Baa2 senior unsecured rating or stable outlook.  Full Article

Photo

EpiPen maker Mylan to restructure, cut workforce

Generic drugmaker Mylan NV , which has been under fire for price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it expected to cut less than 10 percent of its workforce in a restructuring to integrate acquisitions.